ENDRA Life Sciences, a Nasdaq-listed company, has announced a securities purchase agreement to raise $14.4 million through a rights offering. The agreement involves the subscription of 744,340 shares of common stock and warrants for an additional 1,488,680 shares. If all warrants are exercised, the total funds raised will support the company's digital asset treasury. This move aligns with ENDRA's previously disclosed strategy to implement a Bitcoin-based revenue-generating approach.